Register for Upcoming Webinar on DEC. 8 @ 11AM
2026 China NMPA Bluebook is here:
Here’s the latest China NMPA regulatory and clinical affairs news for medical device and IVDs pros in March 2026. These updates are presented by China Med Device, LLC, your partner
In 2025, polydeoxyribonucleotide (PDRN) has rapidly emerged as one of the most closely watched bioactive materials in the global skincare and medical aesthetics industry. Across international ingredient exhibitions, functional skincare
The National Institutes for Food and Drug Control of NMPA released the draft GB/T 16886.1-2025, “Biological Evaluation of Medical Devices — Part 1: Evaluation and Testing Within a Risk Management
NMPA published the “Guideline for Registration of Mobile Medical Devices” on May 7, 2025, replacing the 2017 version. This updated guideline is to facilitate manufacturers with local type testing and
China has applied provisional import tariff rates lower than the most-favored-nation rates on 935 items starting from January 1, 2026, the Customs Tariff Commission of the China State Council announced
Here’s the latest China NMPA regulatory and clinical affairs news for medical device and IVDs pros in February 2026. These updates are presented by China Med Device, LLC, your partner
The Guangdong Provincial Medical Products Administration and the Guangdong Provincial Health Commission issued the “Administrative Measures for the GBA Urgently Needed Hong Kong–Macao Drugs and Medical Devices Catalog” on September
NMPA released the revised Good Manufacturing Practice (GMP) for Medical Devices on November 4, 2025, also referred to as the “Specification for Medical Device Production.” This marks the most substantial
The NMPA issued the “Announcement on Adjustments to Certain Items in the Medical Device Classification Catalog” on January 4, 2026. The adjustments are aimed to keep up with the international
NMPA issued the “2026 Medical Device Industry Standards Revisions Plan” today on January 28, 2026. One mandatory and seventy-nine recommended standards will be revised or established. The standards revisions are
In the review reports released in December 2025, eight out of ten pertained to IVD reagents, reflecting the continued advancement and regulatory scrutiny in fields such as immunology and molecular
Here’s the latest China NMPA regulatory and clinical affairs news for medical device and IVDs pros in January 2026. These updates are presented by China Med Device, LLC, your partner